United Therapeutics Co. (NASDAQ:UTHR) Stock Position Increased by Amalgamated Bank

Amalgamated Bank grew its position in United Therapeutics Co. (NASDAQ:UTHR) by 2.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 22,167 shares of the biotechnology company’s stock after purchasing an additional 602 shares during the period. Amalgamated Bank’s holdings in United Therapeutics were worth $7,821,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Milestone Asset Management LLC increased its position in United Therapeutics by 56.5% in the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after acquiring an additional 1,037 shares during the period. Janney Montgomery Scott LLC grew its stake in shares of United Therapeutics by 9.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after purchasing an additional 789 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of United Therapeutics by 35.4% during the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after purchasing an additional 50,291 shares during the period. Franklin Resources Inc. raised its stake in shares of United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Finally, Burney Co. lifted its holdings in United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after purchasing an additional 12,705 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Down 10.8 %

Shares of NASDAQ UTHR opened at $318.89 on Thursday. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The stock has a market capitalization of $14.24 billion, a price-to-earnings ratio of 14.00, a PEG ratio of 0.97 and a beta of 0.57. The stock’s fifty day simple moving average is $361.17 and its 200 day simple moving average is $360.81.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the previous year, the company earned $4.36 EPS. As a group, analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Activity

In other news, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at $13,743,122.70. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 124,164 shares of company stock worth $45,278,893 over the last 90 days. 11.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on UTHR. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. LADENBURG THALM/SH SH raised their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Argus upped their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.